Trial Profile
An Active Surveillance to Monitor the Real World Safety in Indian Patients Prescribed Nintedanib for the Treatment of Locally Advanced, Metastatic or Locally Recurrent Non Small Cell Lung Cancer (NSCLC) of Adenocarcinoma Tumor Histology After First Line Chemotherapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Mar 2024
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 12 Oct 2022 Status changed from recruiting to completed.
- 19 Aug 2021 Planned End Date changed from 1 Sep 2021 to 8 Oct 2022.
- 19 Aug 2021 Planned primary completion date changed from 1 Sep 2021 to 8 Oct 2022.